Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...
While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...
Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...
2d
Zacks.com on MSNBiogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance DisappointsBiogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
2don MSN
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...
Leqembi, which Biogen shares with the Japanese drugmaker Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. in 2023. The therapy's launch has ...
Also Read: FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi Rare disease revenue increased 13% year over year (up 15% on constant currency) to $535.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results